BRAF mutation in metastatic colorectal cancer - PubMed (original) (raw)
. 2009 Jul 2;361(1):98-9.
doi: 10.1056/NEJMc0904160.
- PMID: 19571295
- DOI: 10.1056/NEJMc0904160
Free article
BRAF mutation in metastatic colorectal cancer
Jolien Tol et al. N Engl J Med. 2009.
Free article
Erratum in
- N Engl J Med. 2011 Sep 1;365(9):869
No abstract available
Similar articles
- Cetuximab for metastatic colorectal cancer.
Roila F, Garassino MC, Ballatori E. Roila F, et al. N Engl J Med. 2009 Jul 2;361(1):95; author reply 96-7. N Engl J Med. 2009. PMID: 19579279 No abstract available. - Cetuximab for metastatic colorectal cancer.
Bria E, Cuppone F, Di Maio M. Bria E, et al. N Engl J Med. 2009 Jul 2;361(1):95-6; author reply 96-7. N Engl J Med. 2009. PMID: 19579280 No abstract available. - Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. Ince WL, et al. J Natl Cancer Inst. 2005 Jul 6;97(13):981-9. doi: 10.1093/jnci/dji174. J Natl Cancer Inst. 2005. PMID: 15998951 - Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Hochster HS. Hochster HS. Semin Oncol. 2006 Oct;33(5 Suppl 10):S8-14. doi: 10.1053/j.seminoncol.2006.08.005. Semin Oncol. 2006. PMID: 17145525 Review. - Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Beatty GL, Giantonio BJ. Beatty GL, et al. Expert Rev Anticancer Ther. 2008 May;8(5):683-8. doi: 10.1586/14737140.8.5.683. Expert Rev Anticancer Ther. 2008. PMID: 18471041 Review.
Cited by
- EPMA position paper in cancer: current overview and future perspectives.
Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM. Grech G, et al. EPMA J. 2015 Apr 15;6(1):9. doi: 10.1186/s13167-015-0030-6. eCollection 2015. EPMA J. 2015. PMID: 25908947 Free PMC article. - TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients.
Dinami R, Porru M, Amoreo CA, Sperduti I, Mottolese M, Buglioni S, Marinelli D, Maugeri-Saccà M, Sacconi A, Blandino G, Leonetti C, Di Rocco G, Verdina A, Spinella F, Fiorentino F, Ciliberto G, Biroccio A, Zizza P. Dinami R, et al. J Exp Clin Cancer Res. 2020 Jun 15;39(1):111. doi: 10.1186/s13046-020-01612-z. J Exp Clin Cancer Res. 2020. PMID: 32539869 Free PMC article. - Alternate dosing of cetuximab for patients with metastatic colorectal cancer.
Hubbard JM, Alberts SR. Hubbard JM, et al. Gastrointest Cancer Res. 2013 Mar;6(2):47-55. Gastrointest Cancer Res. 2013. PMID: 23745159 Free PMC article. - Microsatellite instability testing and its role in the management of colorectal cancer.
Kawakami H, Zaanan A, Sinicrope FA. Kawakami H, et al. Curr Treat Options Oncol. 2015 Jul;16(7):30. doi: 10.1007/s11864-015-0348-2. Curr Treat Options Oncol. 2015. PMID: 26031544 Free PMC article. Review. - That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
Sale MJ, Cook SJ. Sale MJ, et al. Br J Pharmacol. 2013 Aug;169(8):1708-22. doi: 10.1111/bph.12220. Br J Pharmacol. 2013. PMID: 23647573 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials